07:00 , Apr 7, 2014 |  BC Week In Review  |  Clinical News

GSK1070916: Phase I data

Cancer Research UK (London, U.K.) said a dose-escalation, U.K. Phase I trial in 36 patients with advanced solid tumors showed that GSK1070916 was well tolerated and met undisclosed pre-determined success criteria. Based on the results,...
07:00 , Apr 23, 2007 |  BioCentury  |  Tools & Techniques

Ranking the kinase kingdom

After four years of work, researchers at the Wellcome Trust Sanger Institute and colleagues have elucidated the prevalence and signature of somatic mutations in human protein kinases. The findings, recently reported in Nature , have...